Additional Topics:
Bronchiectasis and COPD
-
Explore the Latest Developments in Bronchiectasis During ATS 2026 Orlando
on
Read more: Explore the Latest Developments in Bronchiectasis During ATS 2026 OrlandoIn August 2025, clinicians and researchers who treat patients with bronchiectasis reached a significant milestone with the FDA approval of brensocatib, the first treatment developed for non-cystic fibrosis bronchiectasis in adults and pediatric patients aged 12 and older. In an interview with ATS Conference News, Dan Belz, MD, MPH, explained the significance of this milestone…
-
ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPD
on
Read more: ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPDRecent reports show that chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death in the United States in 2023, with 141,733 deaths related to the disease during that year. Additionally, treatments for the disease incur annual medical costs of approximately $24 billion for adults aged 45 and older. Spyridon Fortis, MD, PhD,…
-
Bronchiectasis and COPD Lineup at ATS 2026 Orlando
on
Read more: Bronchiectasis and COPD Lineup at ATS 2026 OrlandoATS 2026 Orlando offers a robust scientific program, featuring a variety of scientific symposia, abstract presentations, and Meet the Expert sessions to examine the latest investigative insights and clinical challenges for treating bronchiectasis and COPD.
Interstitial Lung Disease/Pulmonary Fibrosis (ILD/IPF)
-
ILD and IPF Lineup at ATS 2026 Orlando
on
Read more: ILD and IPF Lineup at ATS 2026 OrlandoATS 2026 Orlando offers a robust scientific program featuring a variety of scientific symposia, abstract presentations, and Meet the Expert sessions to examine the latest investigative insights and clinical challenges for treating ILD and IPF.